
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-350
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LM-350 in Subjects with Advanced Solid Tumours
Details : LM-350 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 08, 2025
Lead Product(s) : LM-350
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Sino Biopharmaceutical
Deal Size : $951.0 million
Deal Type : Acquisition
Sino Biopharmaceutical to Acquire LaNova Medicines for up to $951 million
Details : Upon completion of the acquisition, LaNova will become a wholly owned subsidiary of Sino. Its lead product, LM-302, is being evaluated for the treatment of CLDN18.2-positive gastric cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Sino Biopharmaceutical
Deal Size : $951.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-108
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Details : LM-108 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 13, 2025
Lead Product(s) : LM-108
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-168
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LM-168 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : LM-168
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GI-102,LM-302
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : GI Innovation
Deal Size : Undisclosed
Deal Type : Agreement
GI Innovation-LaNova Signs MOU for GI-102 + ADC in Pancreatic Cancer Therapy
Details : Through this agreement, both companies will conduct clinical trial of GI-102 in combination with LM-302 targeting patients with metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : GI-102,LM-302
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : GI Innovation
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,288.0 million
Deal Type : Licensing Agreement
Merck Licenses LM-299, An Anti-PD-1/VEGF Bispecific Antibody for Global Development
Details : The agreement aims to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $588.0 million
December 20, 2024
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,288.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,288.0 million
Deal Type : Licensing Agreement
Merck Signs Up to $3.3 Billion Cancer Drug Deal with China-Based Lanova
Details : Merck will acquire the global rights to develop and market LM-299, a novel investigational PD-1/VEGF bispecific antibody, for the treatment of advanced solid tumours.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $588.0 million
November 16, 2024
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,288.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-2417
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Details : LM-2417 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 12, 2024
Lead Product(s) : LM-2417
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of LM-299 in Subjects Advanced Malignant Tumors
Details : LM-299 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : LM-299
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sino Biopharmaceutical
Deal Size : $42.0 million
Deal Type : Series C Financing
LaNova Initiates Phase 1 for LM-299 Anti-PD-1/VEGF Antibody and $42M Financing
Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sino Biopharmaceutical
Deal Size : $42.0 million
Deal Type : Series C Financing
